| |
POSTER
Safety and Efficacy of Lopinavir/Ritonavir in
Women in a Phase III Study of Antiretroviral-Naïve Subjects
P. Cernohous, B. Bernstein, J. Moseley, M. King, E. Bauer, and
E. Sun
Abbott Laboratories, Abbott Park, IL, for the M98-863 Study Group
 PDF
Poster
|
|
| |
POSTER
Virological response and safety at 48 weeks of double
boosted protease inhibitors
with Lopinavir/R plus either Saquinavir or Amprenavir in heavily
pretreated HIV
infected patients
C Zala, P Patterson, P Coll, et al.
PowerPoint Poster
Abstract
Intensification therapy with lopinavir/ ritonavir in
heavily pretreated patients with virological
failure
J Blanco, J Mallolas, M Arnedo, et al
Abstract
Safety and efficacy of a lopinavir/ritonavir
(LPV/r) and tenofovir disoproxil fumarate
(TDF)-containing regimen in treatment-experienced HIV-infected
patients at week 48
P Cimoch, P Ruane, C Mathews, et al
Abstract
Double, boosted salvage therapy with
lopinavir(LOP)/ritonavir(RIT) and saquinavir-sgc(SQR)
in HIV-1 infected patients having failed 3 antiretroviral
classes
GHR Smith, MB Klien, T Murphy, et al
Abstract
Immunologic and virological response to
MegaHAART salvage therapies containing
Lopinavir/Ritonavir (LPV/r) plus second protease
inhibitor for highly experienced
HIV-infected patients
M Torralba, R Rubio, F Pulido, et al
Abstract
Pharmacokinetic (pk) interaction
between lopinavir/ritonavir (LPV/r) and amprenavir
(APV)
does not affect virologic response to the
combination of LPV/r, APV and RTV in HIV-infected
patients (pts) with multiple treatment failure
(Puzzle 1-ANRS104 Study)
G Raguin, A-M Taburet, G Chene, et al
Abstract
|
Efficacy of regimes containing
Lopinavir/ritonavir (Kaletra) in highly protease
inhibitor- experienced HIV+ patients. Six months
follow-up
C Tural, D Fuster, A Ballesteros, et
al
Abstract
|
|
|
|
Lipidic alterations in AIDS patients in use of
antiretroviral therapy regimen containing lopinavir/ritonavir
J Ribeiro, NAS Santos, JHS Pilotto, et al
Abstract
|
|
Decreased plasma concentrations of Amprenavir
and Lopinavir in HIV patients on this
combination
T J Vanig, M Brill
Abstract
Lopinavir/ritonavir-Efavirenz: preliminary
assessment of a potent nucleoside-sparing dual antiretroviral
regimen (the BIKS study)
C Allavena, A Lafeuillade, M Bentata, et al
Abstract
The
efficacy of lopinavir/ritonavir in multiple PI/NNRTI
experienced patients
ELC Ong , M Mustafa , Y Drew , et al
Abstract
Safety, efficacy and resistance profile
under the new protease inhibitor Lopinavir/ritonavir;
48 week results
E Voigt , J Wasmuth , D Braitinger,
et al
Abstract
|
|
Clinical efficacy of salvage regimens
containing both amprenavir and lopinavir/ritonavir
as compared to salvage regimens containing only
lopinavir/ritonavir stratified by
NNRTI-experience
M Loutfy, C Thompson, M Trpeski, et al
Abstract
|
|
|
Safety and tolerability of lopinavir /
ritonavir (ABT-378/r) during the early access program
(EAP) in a center from Buenos Aires
N Porteiro, H Mingrone, L Ré, et al
Abstract
|
Long
term efficacy of treatment in HIV-1 experienced patients with
lopinavir and ritonavir
E Raise, P Bechi, E Narne, M Bechi,
et al
Abstract
Treatment with lopinavir/ritonavir in
pluriexperienced HIV-infected patients : clinical and
immunological follow up
V Guazzi, E Pinter, C Milito, et al
Abstract
|
|
Steady state pharmacokinetic (PK) of Lopinavir (LPV) in combination
with Nevirapine (NVP) or Efavirenz (EFV)
O Degen, M Kurowski, J van Lunzen, et al
Abstract
The pharmacokinetic interaction of
lopinavir/ritonavir and amprenavir in clinical practice
HE Reynolds, S E Gibbons, J Tjia, et al
Abstract
Drug interaction between amprenavir and lopinavir/ritonavir
in salvage therapy
H Khanlou , E Graham , M Brill, et al
Abstract
|
|
|
Influence of lopinavir / ritonavir therapy on small dense LDL
subfraction
STE Badiou, C Merle De Boever, A M Dupuy, et al
Abstract
Safety and tolerability of lopinavir / ritonavir
(ABT-378/r) during the early access program
EAP) in a center from Buenos Aires
N
Porteiro, H Mingrone, L Ré, et al
Abstract
Lopinavir/Ritonavir: High efficacy and low
drop-out rates despite of metabolic toxicities
E Gersbacher, E Wolf, J Schardt, et al
Abstract
Therapeutic drug monitoring of Iopinavir:
plasma levels of each point of time are
representative
P Langmann, M Zilly, T Vaeth, H Winzer,
et al
Abstract
Steady-state Pharmacokinetics of
double boosting regimen of Lopinavir, plus Minidose
Ritonavir, plus Saquinavir Soft-Gel in HIV-infected
adults
E Ribera, M Diaz, L Pou, et al
Abstract
Lopinavir/r Containing-Regimens
in Heavily Pre-treated HIV-Infected Patients.
Brazilian
Experience
MS Oliveira, MIB Lopes, OHM Leite, et
al
Abstract
Efficacy of lopinavir/r
(Kaletra) in HIV- infected patients with
severe immune deficiency
and/or high viral load
G Fätkenheuer, A Rieke A
Wöhrmann, et al
Abstract
Virologic and immunologic
responses of 292 ARV-experienced
patients enrolled in the
lopinavir/ritonavir expanded access
program in Toronto, Canada
M Loutfy, C Thompson, M
Trpeski, et al
Abstract
|
Lopinavir+Abacavir+Stavudine in the
salvage treatment of multitreated HIV
patients
with failures to multiples previous
antivirals
FGM Feregrino-Goyos, ADR
Alvarado-Diez Rocio, RC Ruiz-Campos
Omar, et al
Abstract
Salvage treatment
with lopinavir/ritonavir (Kaletra)
in HIV-infected patients failing all
current antiretroviral drug families
C de mendoza
Abstract
|
|
|
|
|
|
|
1 year follow up of salvage therapy (ST) with
lopinavir/ritonavir and amprenavir based
combinations in children failing previous highly active
anti-retroviral therapy (HAART)
regimens
M Mathur, E Handelsman, K Tizer, N Desai
Abstract
|
|
|
|
|
|
KLS
Main Page